• Corpus ID: 228063982

Unpacking the Drop in COVID-19 Case Fatality Rates: A Study of National and Florida Line-Level Data.

  title={Unpacking the Drop in COVID-19 Case Fatality Rates: A Study of National and Florida Line-Level Data.},
  author={Cheng Cheng and Helen Zhou and Jeremy C. Weiss and Zachary Chase Lipton},
  journal={AMIA ... Annual Symposium proceedings. AMIA Symposium},
Since the COVID-19 pandemic began, the United States's case fatality rate (CFR) has plummeted. Using national and Florida data, we unpack the drop in CFR between April and December 2020, accounting for such confounders as expanded testing, age distribution shift, and detection-to-death lags. Guided by the insight that treatment improvements in this period should correspond to decreases in hospitalization fatality rate (HFR), and using a block-bootstrapping procedure to quantify uncertainty, we… 
SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency
A statistical approach is developed to produce adjusted estimates of seroprevalence from raw serosurvey results that account for these sources of spectrum bias, and provides a tool for practitioners to generate adjusted estimates with pre-set or custom parameter values.


Decreased Case Fatality Rate of COVID-19 in the Second Wave: a study in 53 countries or regions.
Of 53 countries or regions with the highest death tolls, 43 had lower CFR estimates in the on-going second wave than in the first wave, and the possible reasons are discussed.
Trends in Covid-19 risk-adjusted mortality rates in a single health system
It is found that changes in demographics and severity of illness at presentation account for some, but not all, of the decrease in unadjusted mortality, and mortality was significantly lower towards the end of the study period.
Covid-19: death rate is 0.66% and increases with age, study estimates
The overall death rate from covid-19 has been estimated at 0.66%, rising sharply to 7.8% in people aged over 80 and declining to 0.0016% in children aged 9 and under.1 The estimates, calculated by
Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America
How different lockdown strategies and PCR testing capability adopted by Italy, France, Germany, Spain, Sweden, UK and USA have influenced the Case Fatality Rate and the viral mutations spread is analysed.
Overall decrease in SARS-CoV-2 viral load and reduction in clinical burden: the experience of a hospital in northern Italy
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Remdesivir for the Treatment of Covid-19 — Final Report
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14, and these findings do not support the use of hydroxy chloroquine for treatment of CO VID-19 among hospitalized adults.
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity and was not associated with a reduction in progression to severe covid-19 or all cause mortality.